NuVasive signs definitive agreement to acquire Osteocel biologics business from Osiris Therapeutics
NuVasive, Inc. , a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it has signed a definitive agreement to acquire the Osteocel biologics business from Osiris Therapeutics, Inc. .
Astellas Pharma, a pharmaceutical company, and OSI Pharmaceuticals, a biotechnology company, have entered into a definitive merger agreement under which Astellas will acquire OSI.